BIIB · Biogen Inc
Price
Snapshot
50 fields · last close| Market Cap | $33.17B |
| P/E | 39.72 |
| Float | 147.4M |
| Beta | 0.12 |
| Volatility | 5.0% |
| Exchange | NASDAQ |
| Sector | Biotechnology |
| Cap tier | Large cap |
| Macro sensitivity | Low |
| Clavix score | 77 |
| Price | 220.95 |
| Change | −1.59% |
| Prev Close | 224.51 |
| Open | 225.44 |
| Day Low | 221.23 |
| Day High | 225.80 |
| Avg Vol | 1 |
| Avg $ Vol | $162.2M |
| 52W High | 225.59 |
| 52W Low | 135.39 |
| 52W Pos | 94.9% |
| From High | −2.06% |
| From Low | +63.20% |
| Max DD 1Y | −14.34% |
| Spread | 0.10% |
| Liquidity | Normal |
| SMA 20 | +2.71% |
| SMA 50 | +5.64% |
| SMA 200 | +15.82% |
| RSI (14) | 63.5 |
| Vol 30D | 26.7% |
| Vol 90D | 37.8% |
| 1Y Range | 135–226 |
| Daily bars | 863 |
| Perf Week | +1.36% |
| Perf Month | +8.65% |
| Perf Quarter | +14.28% |
| Perf Half Y | +19.37% |
| Perf Year | +58.53% |
| Perf YTD | +24.25% |
| Prev Day | −1.59% |
| Clavix | B+ |
| Debt / Eq | 0.42 |
| Curr Ratio | 2.68 |
| Int Cover | 3.4× |
| FCF Margin | 20.7% |
| Rev Growth | +0.0% |
| Profit | Profitable |
| Leverage | Low |
| Sector rank | 6 / 35 |
What BIIB does
Biogen Inc. discovers, develops, manufactures, and delivers therapies in the United States, Europe, Germany, Asia, and internationally.
The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, and TYSABRI for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; SKYCLARYS to treat Friedreich's Ataxia; QALSODY for treating amyotrophic lateral sclerosis; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE.
It offers LEQEMBI for the treatment of Alzheimer’s disease; ZURZUVAE for the treatment of postpartum depression; RITUXAN to treat non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for aRelapsed or refractory diffuse large B-cell lymphoma; and other anti-CD20 therapies.
Biogen Inc. has collaboration and license agreements with Merz Therapeutics; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; UCB; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis; and Sage Therapeutics, Inc., as well as collaborations with Stoke Therapeutics, Inc. for the development and commercialization of zorevunersen, a disease modifying medicine for the treatment of Dravet syndrome; Dayra Therapeutics, Inc. to develop oral macrocyclic peptides; Vanqua Bio, Inc. for developing Vanqua's preclinical oral C5aR1 antagonist compound; City Therapeutics, Inc. to develop select novel RNAi therapies; and ALTEOGEN Inc. to develop subcutaneous (SC) formulations of biologics utilizing ALT-B4.
The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.
Clavix risk grade
regraded every trading dayBIIB grades B+, 77 of 100. Steadiest on Macro Resilience (72), most exposed on Price Stability (60, mixed). 2 of the 4 weighted dimensions sit above the Biotechnology median. Ranks 6 of 35 in Biotechnology by Clavix score.
How rough the ride is
| BIIB | Biotechnology median | |
|---|---|---|
| Betavs the overall market · lower is steadier | 0.12 | 0.50 |
| Volatilityannualized | 5.0% | 13.2% |
| Max drawdown, past yearworst peak-to-trough fall | −14.3% | — |
| Typical daily movemedian absolute daily change | 1.20% | — |
| Days beyond ±3%of the last 252 sessions | 3012% | — |
How its days are spread
Daily returns over the last 252 sessions in 1% bins. Moves beyond ±6% land in the end bins.
52-week range
The bar runs from the lowest to the highest close of the last 252 sessions; the marker is the latest close.
Drawdown from the 1-year peak
Percent below the running high over the last 12 months. Zero is a fresh high.
Market sensitivity
| BIIB | Biotechnology median | |
|---|---|---|
| Beta to the markethow much it swings with the S&P 500 · lower is safer | 0.12 | 0.50 |
| Macro sensitivityrate, dollar and credit exposure bucket | Low | Low56% of 36 |
Where it sits on the macro scale
Low means rates, the dollar and credit spreads barely move it. Very High means they drive a large share of its swings. The counts are how many Biotechnology names sit in each bucket.
Where it ranks in its sector
Rank by Clavix score within the sector. Right is the top of the sector.
Price performance
| BIIB | |
|---|---|
| 1 week | +1.4% |
| 1 month | +8.7% |
| Year to date | +24.3% |
| 1 year | +58.5% |
Context for the rank, not itself a risk measure.
Recent coverage, scored
| BIIB | |
|---|---|
| Articles scoredthe most recent scored coverage, up to 30 | 30since 24 Jul |
| Average score0 most bearish, 100 most bullish | 68 |
| Bullish · bearisharticles above 60 · below 40 | 25 · 1 |
| Directionarticles whose tone is improving vs worsening | 25 ↑ 1 ↓ |
Where the article scores land
Each bar is a 10-point band of article scores. Below 40 reads bearish, above 60 bullish.
Balance sheet, against the sector
The shaded band is the middle half of the 36 Biotechnology names Clavix covers; the tick is the sector median.
Growth
| BIIB | |
|---|---|
| Revenue growthyear over year | +0.0% |
Financial Health is shown but does not count toward the grade. Why
0–100, higher is safer. The tick on each bar is the Biotechnology median. Click a dimension for the evidence behind it. Financial Health is shown but does not count toward the grade.
Against Biotechnology
36 companies| Metric | BIIB | Sector spread | Median |
|---|---|---|---|
| Beta | 0.12 | 0.50 | |
| Volatility | 5.0% | 13.2% | |
| P/E | 39.72 | 22.77 | |
| Debt / equity | 0.42 | 0.24 | |
| Current ratio | 2.68 | 3.73 | |
| FCF margin | 20.7% | 29.1% | |
| Interest coverage | 3.4× | -0.2× |
Recent news
most recent scored articles · the chip is the article’s score · click to openStoke Therapeutics and Biogen presented 4-year data from Phase 1/2a open-label extension studies at the 16th European Epilepsy Congress showing that zorevunersen, when added to standard anti-seizure medicines, produced substantial and lasting reductions in seizures and continued improvements in cognition and behavior in patients with Dravet Syndrome.
Stoke Therapeutics and Biogen are presenting clinical data on zorevunersen, an experimental treatment for Dravet syndrome (a rare severe form of epilepsy), at the European Epilepsy Congress. The 4-year results from the Phase 1/2a open-label extension studies suggest the drug may have lasting, disease-modifying effects.
China approved Biogen's drug felzartamab (sold as Jingfei) for second-line treatment of adults with multiple myeloma, making it the third CD38-targeting antibody approved there after Johnson & Johnson's daratumumab and Sanofi's isatuximab. GlobalData projects the drug will capture 14.6% of the Chinese multiple myeloma market by 2029.
The article announces that LEQEMBI IQLIK, an at-home autoinjector version of the Alzheimer's drug lecanemab, is now available in the U.S. for both starting and ongoing treatment. The body text simply repeats the headline and offers no additional details.
Eisai announced that LEQEMBI IQLIK, an at-home autoinjector for the Alzheimer's drug lecanemab, is now available in the U.S. for starting treatment. This article is from Eisai and does not report a development at Biogen.
Nearest peers by size
Biotechnology| Ticker | Company | Grade | Mkt cap | P/E | Beta | |
|---|---|---|---|---|---|---|
| ALNY | Alnylam Pharmaceuticals Inc | C | $35.39B | 44.28 | 0.34 | Compare |
| INSM | Insmed Inc | C- | $27.66B | — | 0.82 | Compare |
| INCY | Incyte Corp | B+ | $25.95B | 16.10 | 0.78 | Compare |
| RVMD | Revolution Medicines Inc | B- | $45.20B | — | 1.44 | Compare |
| NTRA | Natera Inc | B- | $47.23B | — | 1.61 | Compare |
| UTHR | United Therapeutics Corp | A- | $21.89B | 16.03 | 0.51 | Compare |
| MRNA | Moderna Inc | F | $59.43B | — | 1.22 | Compare |
| ASND | Ascendis Pharma A/S | B+ | $16.91B | 19.37 | 0.38 | Compare |
You just read one holding. Clavix reads the whole portfolio.
Every position you own, graded on the same five dimensions, with an alert when a grade moves. Three months free on iPhone.